Logo image of PACB

PACIFIC BIOSCIENCES OF CALIF (PACB) Stock Fundamental Analysis

USA - NASDAQ:PACB - US69404D1081 - Common Stock

1.27 USD
-0.01 (-0.78%)
Last: 9/19/2025, 8:00:02 PM
1.27 USD
0 (0%)
After Hours: 9/19/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, PACB scores 2 out of 10 in our fundamental rating. PACB was compared to 55 industry peers in the Life Sciences Tools & Services industry. PACB may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, PACB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PACB had negative earnings in the past year.
PACB had a negative operating cash flow in the past year.
In the past 5 years PACB reported 4 times negative net income.
PACB had negative operating cash flow in 4 of the past 5 years.
PACB Yearly Net Income VS EBIT VS OCF VS FCFPACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -63.76%, PACB is doing worse than 87.27% of the companies in the same industry.
PACB's Return On Equity of -856.02% is on the low side compared to the rest of the industry. PACB is outperformed by 94.55% of its industry peers.
Industry RankSector Rank
ROA -63.76%
ROE -856.02%
ROIC N/A
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
PACB Yearly ROA, ROE, ROICPACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

The Gross Margin of PACB (24.00%) is worse than 78.18% of its industry peers.
PACB's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for PACB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
PACB Yearly Profit, Operating, Gross MarginsPACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

3

2. Health

2.1 Basic Checks

PACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
PACB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PACB has been increased compared to 5 years ago.
PACB has a worse debt/assets ratio than last year.
PACB Yearly Shares OutstandingPACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
PACB Yearly Total Debt VS Total AssetsPACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

PACB has an Altman-Z score of -5.62. This is a bad value and indicates that PACB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PACB (-5.62) is worse than 87.27% of its industry peers.
PACB has a Debt/Equity ratio of 10.51. This is a high value indicating a heavy dependency on external financing.
PACB has a worse Debt to Equity ratio (10.51) than 94.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.51
Debt/FCF N/A
Altman-Z -5.62
ROIC/WACCN/A
WACC6.23%
PACB Yearly LT Debt VS Equity VS FCFPACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

PACB has a Current Ratio of 6.92. This indicates that PACB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.92, PACB belongs to the top of the industry, outperforming 87.27% of the companies in the same industry.
PACB has a Quick Ratio of 6.02. This indicates that PACB is financially healthy and has no problem in meeting its short term obligations.
PACB has a Quick ratio of 6.02. This is amongst the best in the industry. PACB outperforms 85.45% of its industry peers.
Industry RankSector Rank
Current Ratio 6.92
Quick Ratio 6.02
PACB Yearly Current Assets VS Current LiabilitesPACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

PACB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -52.67%.
Looking at the last year, PACB shows a very negative growth in Revenue. The Revenue has decreased by -17.35% in the last year.
PACB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.12% yearly.
EPS 1Y (TTM)-52.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.13%
Revenue 1Y (TTM)-17.35%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%10.42%

3.2 Future

PACB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.41% yearly.
PACB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.20% yearly.
EPS Next Y8.23%
EPS Next 2Y29.12%
EPS Next 3Y20.5%
EPS Next 5Y12.41%
Revenue Next Year3.49%
Revenue Next 2Y9.42%
Revenue Next 3Y13.28%
Revenue Next 5Y14.2%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PACB Yearly Revenue VS EstimatesPACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
PACB Yearly EPS VS EstimatesPACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PACB. In the last year negative earnings were reported.
Also next year PACB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PACB Price Earnings VS Forward Price EarningsPACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PACB Per share dataPACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as PACB's earnings are expected to grow with 20.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.12%
EPS Next 3Y20.5%

More info and screens

0

5. Dividend

5.1 Amount

PACB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACIFIC BIOSCIENCES OF CALIF

NASDAQ:PACB (9/19/2025, 8:00:02 PM)

After market: 1.27 0 (0%)

1.27

-0.01 (-0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners62.48%
Inst Owner Change-12.93%
Ins Owners0.99%
Ins Owner Change21.21%
Market Cap381.47M
Analysts75.79
Price Target2.04 (60.63%)
Short Float %13.6%
Short Ratio5.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-313.85%
Min EPS beat(2)-646.96%
Max EPS beat(2)19.26%
EPS beat(4)2
Avg EPS beat(4)-189.42%
Min EPS beat(4)-646.96%
Max EPS beat(4)19.26%
EPS beat(8)3
Avg EPS beat(8)-114.36%
EPS beat(12)4
Avg EPS beat(12)-75.63%
EPS beat(16)5
Avg EPS beat(16)-58.32%
Revenue beat(2)2
Avg Revenue beat(2)4.48%
Min Revenue beat(2)3.35%
Max Revenue beat(2)5.6%
Revenue beat(4)2
Avg Revenue beat(4)-0.48%
Min Revenue beat(4)-6.61%
Max Revenue beat(4)5.6%
Revenue beat(8)3
Avg Revenue beat(8)-1.93%
Revenue beat(12)6
Avg Revenue beat(12)0.24%
Revenue beat(16)7
Avg Revenue beat(16)0.1%
PT rev (1m)2.09%
PT rev (3m)3%
EPS NQ rev (1m)-0.16%
EPS NQ rev (3m)2.99%
EPS NY rev (1m)-1.15%
EPS NY rev (3m)-84.83%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)0.83%
Revenue NY rev (1m)2.69%
Revenue NY rev (3m)2.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.44
P/FCF N/A
P/OCF N/A
P/B 6.2
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.5
OCFYN/A
SpS0.52
BVpS0.2
TBVpS-0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.76%
ROE -856.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24%
FCFM N/A
ROA(3y)-19.98%
ROA(5y)-12.37%
ROE(3y)-53.57%
ROE(5y)-34.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.03%
GM growth 5Y-8.17%
F-Score2
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 10.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.89%
Cap/Sales 4.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.92
Quick Ratio 6.02
Altman-Z -5.62
F-Score2
WACC6.23%
ROIC/WACCN/A
Cap/Depr(3y)69.29%
Cap/Depr(5y)60.46%
Cap/Sales(3y)7.21%
Cap/Sales(5y)5.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-52.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.13%
EPS Next Y8.23%
EPS Next 2Y29.12%
EPS Next 3Y20.5%
EPS Next 5Y12.41%
Revenue 1Y (TTM)-17.35%
Revenue growth 3Y5.68%
Revenue growth 5Y11.12%
Sales Q2Q%10.42%
Revenue Next Year3.49%
Revenue Next 2Y9.42%
Revenue Next 3Y13.28%
Revenue Next 5Y14.2%
EBIT growth 1Y-77.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year67.05%
EBIT Next 3Y20.48%
EBIT Next 5Y16.58%
FCF growth 1Y42.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3YN/A
OCF growth 5YN/A